The AGNP-TDM expert group consensus guidelines: Therapeutic Drug Monitoring in psychiatry

Pharmacopsychiatry

Volumn 37, Issue 6, 2004, Pages 243-265

  Baumann, Pierre ^a,m   Hiemke, C ^b   Ulrich, S ^c   Eckermann, G ^d   Gaertner, I ^e   Gerlach, M ^f   Kuss, H J ^g   Laux, G ^h   Muller Oerlinghausen B ^i,j   Rao, M L ^k   Riederer, P ^f   Zernig, G ^l  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d Bezirkskrankenhaus Kaufbeuren   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h Bezirksklinikum Gabersee ^*  (Germany)

ⁱ Drug Commn of the Ger Med Assoc   (Germany)

^j Drug Commn of the Ger Med Assoc   (Germany)

^k UNIVERSITY OF BONN   (Germany)

^l UNIVERSITY OF INNSBRUCK   (Austria)

^m DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; ESCITALOPRAM; FLUOXETINE; HALOPERIDOL DECANOATE; IMIPRAMINE; LITHIUM; MIANSERIN; MOCLOBEMIDE; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; REBOXETINE; RISPERIDONE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; VILOXAZINE; ZIPRASIDONE;

CLINICAL PRACTICE; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG COST; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; MAJOR DEPRESSION; MEDICAL SOCIETY; META ANALYSIS; PATIENT COMPLIANCE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHIATRY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TOXICITY;

DRUG MONITORING; HUMANS; MENTAL DISORDERS; PSYCHIATRY; PSYCHOTROPIC DRUGS;

EID: 9744251578     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-832687     Document Type: Review

References (278)

1. Adler L, Hajak G, Lehmann K, Kunert H-J, Hoffmann G, Issinger J et al. On the problems of switching from intravenous to oral administration in drug treatment of endogenous depression - A placebo-controlled double-blind trial with Doxepin. Pharmacopsychiatry 1997; 30: 62-69
2. Alexanderson BH, Evans DA, Sjöqvist S. Steady-state plasma levels of nortriptyline in twins: influence of genetic factors and drug therapy. Br Med J 1969; 686: 764-768
3. Altamura AC, Mauri MC, Guercetti G. Age, therapeutic "milieu" and clinical outcome in depressive patients treated with viloxazine. Prog Neuropsychopharmacol Biol Psychiatry, 1986
4. American Academy of Pediatrics. Use of psychoactive medication during pregnancy and possible effects on the fetus and newborn. Pediatrics, 2000; 105: 880-887
5. American Psychiatric Association Practice Guidelines. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry, 2000; 157 Supplement(4)
6. Amsterdam JD, Brunswick DJ, Winokur A, Rickels K. Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients. Arch Gen Psychiatry 1985; 42: 361-364
7. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997; 154: 963-969
8. Aravagiri M, Marder SR, Wirshing D, Wirshing WC. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 1998; 31: 102-109
9. Åsberg M, Cronholm B, Sjoqvist F, Tuck D. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 1970; 4(726): 18-21
10. Åsberg M, Cronholm B, Sjoqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971; 3: 331-334
11. Åsberg M, Sjöqvist F. On the role of plasma level monitoring of tricyclic antidepressants in clinical practice. Comm Psychopharmacol 1978; 2: 381-391
12. Axelson DA, Perel JM, Birmaher B, Rudolph GR, Nuss S, Bridge J et al. Sertraline pharmacokinetics and dynamics in adolescents. J Am Acad Child Adolesc Psychiatry 2002; 41(9): 1037-1044
13. Bailey B, McGuigan M. Lithium poisoning from a poison control center perspective. Ther Drug Monit 2000; 22(6): 650-655
14. Balant-Gorgia AE, Balant L. Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 1987; 13: 65-90
15. Balant-Gorgia AE, Eisele R, Aeschlimann JM, Balant LP, Garrone G. Plasma flupentixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit 1985; 7(4): 411-414
16. Balant-Gorgia EA, Balant LP. Therapeutic drug monitoring - Relevance during the drug treatment of psychiatric disorders. CNS Drugs 1995; 4: 432-453
17. Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79-91
18. Banger M, Hermes B, Härtter S, Hiemke C. Monitoring serum concentrations of clomipramine and metabolites: fluorescence polarization immunoassay versus high performance liquid chromatography. Pharmacopsychiatry 1997; 30: 128-132
19. Baptista T, Teneud L, Contreras Q, Alastre T, Burguera JL, de Burguera M et al. Lithium and body weight gain. Pharmacopsychiatry 1995; 28: 35-44
20. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry 2002; 3: 5-43
21. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-469
22. Baumann P, Eap CB. Pharmacogenetics of chiral psychotropic drugs. In: Lerer B, editor. Pharmacogenetics of Psychotropic Drugs Cambridge: Cambridge university press, 2002: 181-214
23. Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao ML, Eckermann G et al. Therapeutic monitoring of psychotropic drugs - An outline of the AGNP-TDM expert group consensus guideline. Ther Drug Monit 2004; 26(2): 167-170
24. Baumann P, Jonzier-Perey M, Koeb L, Le PK, Tinguely D, Schöpf J. Amitriptyline pharmacokinetics and clinical response: I. Free and total plasma amitriptyline and nortriptyline. Int Clin Psychopharmacol 1986; 1: 89-101
25. Baumann P, Kahn JM. Les médicaments ǵnériques: quels sont les problèmes et d'où viennent-ils?. Med Hyg 2003; 61 (2434): 879-884
26. Baumann P, Meyer JW, Amey M, Baettig D, Bryois C, Jonzier-Perey M et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992; 14: 1-8
27. Baumann P, Nil R, Bertschy G, Jecker A, Brändli H, Morand J et al. A double-blind double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord 1998; 49: 203-210
28. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S et al. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 1996; 16: 307-314
29. Baumann P, Zullino DF, Eap CB. Enantiomers' potential in psychopharmacology - a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433-444
30. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994; 14(2): 111-118
31. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23(3): 229-232
32. Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20(4): 215-219
33. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's The pharmacological basis of therapeutics New York: McGraw-Hill Companies, 1996: 3-27
34. Bengtsson F. Therapeutic drug monitoring of psychotropic drugs TDM "nouveau". Ther Drug Monit 2004; 26(2): 145-151
35. Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. European Neuropsychopharmacology 2004; 14: 245-250
36. Bertilsson L, Dahl ML. Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders. CNS Drugs 1996; 5: 200-223
37. Bertilsson L, Mellström B, Sjöqvist F, Mȧrtensson B, Åsberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1981; i: 560-561
38. Bjerkenstedt L, Flyckt L, Overø KF, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985; 28: 553-557
39. Bjorndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH et al. High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology 1980; 67(1): 17-23
40. Bondolfi G, Chautems C, Rochat B, Bertschy G, Baumann P. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psychopharmacology 1996; 128: 421-425
41. Bondolfi G, Eap CB, Bertschy G, Zullino D, Vermeulen A, Baumann P. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002; 35: 50-56
42. Bondolfi G, Lissner C, Kosel M, Eap CB, Baumann P. Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences. Int J Neuropsychopharmacol 2000; 3: 55-60
43. Bork JA, Rogers T, Wedlund PJ, De Leon J. A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469-476
44. Bowden CL, Janicak PG, Orsulak P, Swann AC, Davis JM, Calabrese JR et al. Relation of serum valproate concentration to response in mania. Am J Psychiatry 1996; 153: 765-770
45. Breyer-Pfaff U, Brinkschulte M, Rein W, Schied HW, Straube E. Prediction and evaluation criteria in perazine therapy of acute schizophrenics pharmacokinetic data. Pharmacopsychiatry 1983; 16: 160-165
46. Breyer-Pfaff U, Gaertner HJ. Antidepressiva Pharmakologie, therapeutischer Einsatz und Klinik der Depression. Wissenschaftliche Verlagsgesellschaft GmbH, Stuttgart: 1987
47. Breyer-Pfaff U, Gaertner HJ, Giedke H. Plasma levels, psychophysiological variables, and clinical response to amitriptyline. Psychiatry Res 1982; 6(2): 223-234
48. Breyer-Pfaff U, Gaertner HJ, Kreuter F, Scharek G, Brinkschulte M, Wiatr R. Antidepressive effect and pharmacokinetics of amitriptyline with consideration of unbound drug and 10-hydroxynortriptyline plasma levels. Psychopharmacology 1982; 76(3): 240-244
49. Brinkmann U, Eichelbaum M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics 2001; 1: 59-64
50. Brockmöller J, Kirchheiner J, Schmider J, Walter S, Sachse C, Müller-Oerlinghausen B et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72(4): 438-452
51. Broich K, Heinrich S, Marneros A. Acute clozapine overdose: plasma concentration and outcome. Pharmacopsychiatry 1998; 31: 149-151
52. Brøsen K. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther Drug Monit 1996; 18: 93-396
53. Buick AR, Doig MV, Jeal SC, Und GS, Mcdowall RD. Method validation in the bioanalytical laboratory. J Pharm Biomed Anal 1990; 8: 629-637
54. Burch JE, Raddats MA. Time course of plasma drug levels during once-daily oral administration of clomipramine. Psychopharmacology 1982; 77: 344-347
55. Burchell B. Transformation reactions: glucuronidation. In: Woolf TF, editor. Handbook of drug metabolism New York - Basel: Marcel Dekker. Inc, 1999: 153-173
56. Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants - Cost implications and relevance to clinical practice. Clin Pharmacokinet 1999; 37: 147-165
57. Burt VK, Suri R, Altshuler L, Stowe Z, Hendrick VC, Muntean E. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158(7): 1001-1009
58. Caccia S, Garattini S. Formation of active metabolites of psychotropic drugs: an updated review of their significance. Clin Pharmacokinet 1990; 18: 434-459
59. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine - pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-193
60. Causon R. Validation of Chromatographic methods in biomedical analysis viewpoint and discussion. Journal of Chromatography B 1997; 689: 175-180
61. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding. A review. J Clin Psychiatry 2001; 61: 79-90
62. Chen S, Chou WH, Blouin RA, Mao Z, Humphries LL, Meek C et al. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther 1996; 60: 522-534
63. Chou WH, Van F-X, Barnhill J, Rogers T, Cronin M, Pho M et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246-251
64. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 2002; 159(4): 351-360
65. Cournoyer G, De Montigny C, Ouellette J, Langlois R, Elie R, Caille G et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 1987; 7: 385-393
66. Coutts RT, Urichuk LJ. Polymorphic cytochromes P450 and drugs used in psychiatry. Cell Mol Neurobiol 1999; 19: 325-354
67. Creese I, Snyder SH. A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 1977; 270: 80-182
68. Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41(7): 453-470
69. Dahl ML, Sjöqvist F. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics. Ther Drug Monit 2000; 22: 114-117
70. Danish University Antidepressant Group. Clomipramine dose-effect study in patients with depression: clinical end points and pharmacokinetics. Clin Pharmacol Ther 1999; 66: 152-165
71. Dasberg HH, van der KE, Guelen JP, Van Praag HM. Plasma concentrations of diazepam and of its metabolite N-desmethyldiazepam in relation to anxiolytic effect. Clin Pharmacol Ther 1974; 15(5): 473-483
72. De la Torre R, Ortuño J, Pascual JA, Gonzalez S, Ballesta J. Quantitative determination of tricyclic antidepressants and their metabolites in plasma by solid-phase extraction (bond-elut TCA) and separation by capillary gas Chromatography with nitrogen-phosphorous detection. Ther Drug Monit 1998; 20: 340-346
73. De Leon J. Glucuronidation enzymes, genes and psychiatry, Int J Neuropsychopharmacol 2003; 6: 57-72
74. De Oliveira IR, Dardennes RM, Amorim ES, Diquet B, de Sena EP, Moreira EC et al. Is there a relationship between antipsychotic blood levels and their clinical efficacy? An analysis of studies design and methodology. Fundam Clin Pharmacol 1995; 9: 488-502
75. Deuschle M, Härtter S, Hiemke C, Standhardt H, Heuser I. Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology 1997; 131(1): 19-22
76. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiat 1994; 55(suppl 12): 38-45
77. Divoll M, Greenblatt DJ, Lacasse Y, Shader RI. Benzodiazepine overdosage: plasma concentrations and clinical outcome. Psychopharmacology 1981; 73(4): 381-383
78. Doherty MM, Charman WN. The mucosa of the small intestine - How clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 2002; 41 (4): 235-253
79. Donoghue J, Taylor DM. Suboptimal use of antidepressants in the treatment of depression. CNS Drugs 2000; 13: 365-383
80. Dyson EH, Simpson D, Prescott LF, Proudfoot AT. Self-poisoning and therapeutic intoxication with lithium. Hum Toxicol 1987; 6(4): 325-329
81. Eadie MJ. Formation of active metabolites of anticonvulsant drugs - A review of their pharmacokinetic and therapeutic significance. Clin Pharmacokinet 1991; 21: 27-41
82. Eap CB, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209-214
83. Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F. Nonresponse to clozapine and ultrarapid CYP1A2 activity clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol 2004; 24: 214-219
84. Eap CB, Bourquin M, Martin J-L, Spagnoli J, Livoti S, Powell K et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61: 47-54
85. Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41(14): 1153-1193
86. Eap CB, Guentert TW, Schäublin-Loidl M, Stabl M, Koeb L, Powell K et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322-331
87. Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit 1999; 21: 166-170
88. Eilers R. Therapeutic drug monitoring for the treatment of psychiatric disorders - Clinical use and cost effectiveness. Clin Pharmacokinet 1995; 29: 442-450
89. Ellinwood EH, Jr., Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C, Heatherly DG, Nikaido AM, Bjornsson TD, Kilts C. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology 1985; 86(4): 392-399
90. Ensom MHH, Chang TKH, Patel P. Pharmacogenetics - The therapeutic drug monitoring of the future? Clin Pharmacokinet 2001; 40(11): 783-802
91. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 (suppl. 11): 12-25
92. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 (suppl. 4): 42-55
93. Falcy M, Riboulet-Delmas G, Efthymiou ML. [Acute poisoning by viloxazine chlorhydrate taken by itself]. Encephale 1983; 9(2): 137-144
94. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-544
95. Fawcett J, Stein DJ, Jobson KO, editors. Textbook of treatment algorithms in Psychopharmacology. Chichester (England), New York, Singapore, Ontario: John Wiley & Sons, 1999: 1-205
96. 2 receptors from plasma levels. Psychopharmacology 2000; 149: 1-5
97. Ford JM, Truman CA, Wilcock GK, Roberts CJC. Serum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993; 53: 691-695
98. Friedel RO, Veith RC, Bloom V, Bielski RJ. Desipramine plasma levels and clinical response in depressed outpatients. Comunications in Pychopharmacology 1979; 3: 81-87
99. Fritze J, Laux G, Sofic E, Koronakis P, Schoerlin MP, Riederer P et al. Plasma moclobemide and metabolites: lack of correlation with clinical response and biogenic amines. Psychopharmacology 1989; 99(2): 252-256
100. Furlanut M, Perosa A, Benetello P, Colombo G. Electrochemical detection of benperidol in serum for drug monitoring in humans. Ther Drug Monit 1987; 9(3): 343-346
101. Gabris G, Baumann P, Jonzier-Perey M, Bosshart P, Woggon B, Küpfer A. N-methylation of maprotiline in debrisoquine/mephenitoin-phenotyped depressive patients. Biochem Pharmacol 1985; 34: 409-410
102. Garzone PD, Kroboth PD. Pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 1989; 16(6): 337-364
103. Gelenberg AJ, Carroll JA, Baudhuin MG, Jefferson JW, Greist JH. The meaning of serum lithium levels in maintenance therapy of mood disorders: a review of the literature. J Clin Psychiatry 1989; 50 Suppl.: 17-22
104. Gerstenberg G, Aoshima T, Fukasawa T, Yoshida K, Takahashi H, Higuchi H et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 2003; 167(4): 443-448
105. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Potential of concentration monitoring data for a short half-life drug: Analysis of pharmacokinetic variability for moclobemide. Ther Drug Monit 1995; 17: 39-46
106. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Clomipramine concentration as a predictor of delayed response: a naturalistic study. Eur J Clin Pharmacol 1999; 54: 895-902
107. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53
108. Glassmann AH, Schildkraut JJ, Orsulak PJ, et al. Tricyclic antidepressants, blood level measurements and clinical outcome: an APA task force report. Am J Psychiat 1985; 142: 155-162
109. Goeringer KE, Raymon L, Christian GD, Logan BK. Postmortem forensic toxicology of selective serotonin reuptake inhibitors: a review of pharmacology and report of 168 cases. J Forensic Sci 2000; 45(3): 633-648
110. Goodnick PJ. Pharmacokinetic optimisation of therapy with newer antidepressants. Clin Pharmacokinet 1994; 27: 307-330
111. Gram LF. Plasma level monitoring of tricyclic antidepressants: methodological and pharmacokinetic considerations. Commun Psychopharmacol 1978; 2: 373-380
112. Green M. A practical guide to analytical method validation. Analytical Chemistry News and Features, 1996: 305-309
113. Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet 1981; 6: 89-105
114. Greenblatt DJ. Basic pharmacokinetic principles and their application to psychotropic drugs. J Clin Psychiatry 1993; 54: 8-13
115. Greenblatt DJ, Von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. J Clin Psychiatry 1993; 54: 4-14
116. Greenblatt DJ, Von Moltke LL, Harmatz JS, Shader RI. Human cytochromes and some newer antidepressants: Kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19(Suppl. 1)(5): 23S-35
117. Hammer WM, Brodie BB. Application of isotope derivative technique to assay of secondary amines: estimation of desipramine by acetylation with H3-Acetic anhydride. J Pharmacol Exp Ther 1967; 157: 503-508
118. Hansen LB, Larsen NL. Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacol 1985; 87: 16-19
119. Härtter S, Hermes B, Hiemke C Automated determination of trimipramine and N-desmethyl-trimipramine in human plasma or serum by HPLC with on-line solid phase extraction. J Liq Chromatogr 1995; 18: 3495-3505
120. Härtter S, Wetzel H, Hammes E, Torkzadeh M, Hiemke C. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit 1998; 20: 446-449
121. Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentrations in plasma in schizophrenia: effect of smoking. J Clin Psychopharmacol 1993; 13: 383-390
122. Heller S, Hiemke C, Stroba G, Rieger-Gies A, Daum-Kreysch E, Sachse J, Hartter S. Assessment of Storage and Transport Stability of New Antidepressant and Antipsychotic Drugs for a Nationwide TDM Service (Letter). Therapeutic Drug Monitoring 2004; 26(4): 459-461
123. Hiemke C, Dragicevic A, Gründer G, Härtter S, Sachse J, Vernaleken I et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26(2): 156-160
124. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28
125. Houghton GW, Dennis MJ, Templeton R, Martin BK. A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane). Int J Clin Pharmacol Ther Toxicol 1985; 23(2): 97-100
126. Ilett KF, Blythe TH, Hackett LP, Ong RTT, Tannenbaum DA, Clarke TMF. Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness. Ther Drug Monit 1993; 15: 351-357
127. Ingels M, Beauchamp J, Clark RF, Williams SR. Delayed valproic acid toxicity: a retrospective case series. Ann Emerg Med 2002; 39(6): 616-621
128. Isacsson G, Holmgren P, Druid H, Bergman U. The utilization of antidepressants - a key issue in the prevention of suicide: an analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand 1997; 96: 94-100
129. Iwersen S, Schmoldt A. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. J Anal Toxicol 1996; 20(5): 301-304
130. Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26
131. Jonasson B, Saldeen T. Citalopram in fatal poisoning cases. Forensic Sci Int 2002; 126(1): 1-6
132. Jungkunz G, Kuss HJ. On the relationship of nortriptyline: amitriptyline ratio to clinical improvement of amitriptyline treated depressive patients. Pharmakopsychiatr Neuropsychopharmakol 1980; 13(3): 111-116
133. Kaferstein H, Sticht G, Pluisch F. [Poisoning by perazine-organ distribution and interpretation]. Arch Kriminol 2000; 206(3-4): 82-87
134. 2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553-559
135. Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998; 155: 921-928
136. Kasper S, Dötsch M, Kick H, Vieira A, Möller HJ. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13-21
137. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TCG, Zussman BD et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80 (suppl. 350): 60-75
138. Keck PE, Jr., McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002; 63 Suppl 4: 3-11
139. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104(3): 73-192
140. Kjolbye M, Thomsen K, Rogne T, Rehfelt E, Olesen OV. Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients. Ther Drug Monit 1994; 16(6): 541-547
141. Kollroser M, Schober C. Simultaneous determination of seven tricyclic antidepressant drugs in human plasma by direct-injection HPLC-APCI-MS-MS with an ion trap detector. Ther Drug Monit 2002; 24: 537-544
142. Kondo T, Otani K, Ishida M, Tanaka O, Kaneko S, Fukushima Y. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 1994; 16: 120-124
143. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34: 713-721
144. Kramer Nielsen K, Bresen K, Gram LF, Bech P, Bolwig TG, Sørensen PK et al. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 1992; 43: 405-411
145. Kratzsch C, Frank TP, Kraemer T, Armin AW, Maurer HH. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 2003; 38: 283-295
146. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27(4): 383-391
147. Kupfer DJ, Hanin I, Spiker DG, Grau T, Coble P. Amitriptyline plasma levels and clinical response in primary depression. Clin Pharmacol Ther 1977; 22(6): 904-911
148. Lane HY, Chiu W-C, Chou JCY, Wu S-T, Su MH, Chang WH. Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels. J Clin Psychiatry 2000; 61: 209-214
149. Laux G, Riederer P, editors. Plasmaspiegelbestimmung von Psychopharmaka: Therapeutisches Drug - Monitoring, Versuch einer ersten Standortbestimmung. Stuttgart (Germany): Wissenschaftliche Verlagsgesellschaft mbH Stuttgart, 1992: 7-128
150. Leinonen E, Lepola U, Koponen H, Kinnunen I. The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of citalopram measured with a nonenantioselective method. Ther Drug Monit 1996; 18: 111-117
151. Lerer B, Macciardi F. Pharmacogenetics of antidepressant and moodstabilizing drugs: a review of candidate-gene studies and future research directions, Int J Neuropsychopharmacol 2002; 5: 255-275
152. Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol 2001; 21(4): 432-439
153. Levine B. Jenkins AJ, Queen M, Jufer R, Smialek JE. Distribution of venlafaxine in three postmortem cases. J Anal Toxicol 1996; 20: 502-505
154. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics - Clinical implications. Clin Pharmacokinet 2003; 42(1): 59-98
155. Linder MW, Keck PE, Jr. Standards of laboratory practice: antidepressant drug monitoring. Clin Chem 1998; 44: 1073-1084
156. Liston HL, Markowitz JS, DeVane CL. Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 2001; 21: 500-515
157. Llewellyn A, Stowe ZN. Psychotropic medications in lactation. J Clin Psychiatry 1998; 59(suppl. 2): 41-52
158. Lovell RW, Bunker WW. Lithium assay errors. Am J Psychiatry 1997; 154(10): 1477
159. Lundmark J, Bengtsson F, Nordin C, Reis M, Walinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354-359
160. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 2000; 22: 446-454
161. Lundmark J, Reis M, Bengtsson F. Serum concentrations of fluoxetine in the clinical treatment setting. Ther Drug Monit 2001; 23: 139-147
162. Lundmark J, Thomsen IS, Fjord-Larsen T, Manniche PM, Mengel H, Møller-Nielsen EM et al. Paroxetine: pharmacokinetic and antidepressant effect in the elderly. Acta Psychiatr Scand 1989; 80(suppl. 350): 76-80
163. Madsen AL, Karle A, Rubin P, Cortsen M, Andersen HS, Hemmingsen R. Progressive atrophy of the frontal lobs in first-episode schizophrenia: interaction with clinical course and neuroleptic treatment. Acta Psychiat Scand 1999; 100: 367-374
164. Maguire KP, Norman TR, Burrows GD, Davies B. Blood and plasma concentrations of dothiepin and its major metabolites and clinical response. J Affect Disord 1982; 4: 41-48
165. Mancama D, Arranz MJ, Kerwin RW. Genetic predictors of therapeutic response to clozapine - Current status of research. CNS Drugs 2002; 16(5): 317-324
166. Mancama D, Kerwin RW. Role of pharmacogenomics in individualising treatment with SSRIs. CNS Drugs 2003; 17(3): 143-151
167. Marder SR, Midha KK, van Putten T, Aravagiri M, Hawes EM, Hubbard JW et
168. Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27(4): 596-606
169. Mavissakalian MR, Jones B, Olson S, Perel JM. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol 1990; 10(4): 261-268
170. McEvoy JP, Scheifler PL, Frances A. The expert consensus guideline series - treatment of Schizophrenia 1999. J Clin Psychiatry 1999; 60(Suppl. 11): 12-18
171. McIntyre IM, King CV, Cordner SM, Drummer OH. Postmortem clomipramine: therapeutic or toxic concentrations? J Forensic Sci 1994; 39(2): 486-493
172. McManus P, Mant A, Mitchell P, Birkett D, Dudley J. Co-prescribing of SSRIs and TCAs in Australia: how often does it occur and who is doing it? Br J Clin Pharmacol 2001; 51(1): 93-98
173. Meibohm B, Beierle I, Derendorf H. How important are gender differences in pharmacokinetics. Clin Pharmacokinet 2002; 41(5): 329-342
174. Meredith PA. Generic drugs - Therapeutic equivalence. Drug Safety 1996; 15(4): 233-242
175. Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667-1671
176. Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Otani K et al. Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine in depressed Japanese patients. Pharmacol Toxicol 2001; 88: 267-270
177. Mihara K, Otani K, Tybring G, Dahl ML, Bertilsson L, Kaneko S. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol 1997; 17: 467-471
178. Milner DA, Hall M, Davis GG, Brissie RM, Robinson CA. Fatal multiple drug intoxication following acute sertraline use. J Anal Toxicol 1998; 22: 545-548
179. Molander L, Borgstrom L. Relationship between plasma concentration and arousal in normal subjects after single oral and parenteral doses of melperone, a butyrophenone neuroleptic. Psychopharmacology 1983; 79(2-3): 111-114
180. Monteleone P, Gnocchi G, Delrio G. Plasma trazodone concentrations and clinical response in elderly depressed patients: a preliminary study. J Clin Psychopharmacol 1989; 9(4): 284-287
181. Montgomery SA, Montgomery DB, McAuley R, Rani SJ. Mianserin plasma levels and differential clinical response in endogenous and reactive depression. Acta Psychiatr Belg 1978; 78: 798-812
182. Moulin A, Truffer D, Rauch-Desanti C, Istin M, Grognet JM, Dufour A. Comparison of HPLC and RIA methods applied to the quantification of amisulpride in human plasma. Eur J Drug Metab Pharmacokinet 1991; 3: 507-512
183. Müller MJ, Dragicevic A, Fric M, Gaertner I, Grasmader K, Härtter S et al. Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions? Pharmacopsychiatry 2003; 36(3): 98-104
184. Müller MJ, Härtter S, Köhler D, Hiemke C. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. Pharmacopsychiatry 2001; 34: 27-32
185. Müller-Oerlinghausen B, Fähndrich E. The relationship between pharmacokinetic data and the clinical response in patients treated with maprotiline or clomipramine by intravenous infusion. Pharmacopsychiatry 2002; 18: 100-101
186. Müller-Oerlinghausen B, Rüther E. Clinical profile and serum concentration of viloxazine as compared to amitriptyline. Pharmakopsychiatr Neuropsychopharmakol 1979; 12(4): 321-337
187. Müller-Oerlinghausen B, Schley J. Serumspiegel von Perazin und seinen Metaboliten: Qualitätskontrolle, Kosten, Interpretation und praktische Bedeutung. In: Helmchen H, Hippius H, Tölle R, editors. Therapie mit Neuroleptika - Perazin New York: Georg Thieme Verlag, Stuttgart: 1988: S27
188. Murray M. P450 Enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease. Clin Pharmacokinet 1992; 23: 132-146
189. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803-808
190. Nelson JC. Current status of tricyclic antidepressants in psychiatry: their pharmacology and clinical applications. J Clin Psychiatry 1991; 52: 193-200
191. Nelson JC, Jatlow PI, Mazure C. Desipramine plasma levels and response in elderly melancholic patients. J Clin Psychopharmacol 1985; 5: 217-220
192. Nishikage H, Nakanishi T, Takamitsu Y, Yamamoto J. Sequential changes in the plasma concentration of risperidone following intentional overdose. Clin Neuropharmacol 2002; 25(6): 307-309
193. Norman TR, Burrows GD, Davies BM, Maguire KP, Wurm JM. Viloxazine plasma concentrations and clinical response. J Affect Disord 1980; 2(3): 157-164
194. Ohman D, Norlander B, Peterson C, Bengtsson F. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC. Ther Drug Monit 2001; 23: 27-34
195. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20: 380-384
196. Orsulak PJ. Therapeutic monitoring of antidepressant drugs - Guidelines updated. Ther Drug Monit 1989; 11: 497-507
197. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118-121
198. Otani K, Kaneko S, Sasa H, Kondo T, Fukushima Y. Is there a therapeutic window for plasma concentration of mianserin plus desmethylmianserin. Hum Psychopharmacol Clin Exp 1991; 6: 243-248
199. Otani K, Tybring G, Mihara K, Yasui N, Kaneko S, Ohkubo T et al. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients. Eur J Clin Pharmacol 1998; 53: 347-349
200. Özdemir V, Kalow W, Okey AB, Lam MS, Albers LJ, Reist C et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C→A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol 2001; 21(6): 603-607
201. Pedersen OL, Gram LF, Kristensen CB, Moller M, Thayssen P, Bjerre M et al. Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol 1982; 23: 513-521
202. Pellizzoni C, Poggesi I, Jørgensen NP, Edwards DMF, Paus E, Benedetti MS. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996; 17: 623-633
203. Perry PJ. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations: a retrospective analysis of the literature using logistic regression analysis lin. Pharmacokinet 1987; 13: 381-392
204. Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American olanzapine trial. J Clin Psychopharmacol 2001; 21: 14-20
205. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235
206. Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely 111 schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472-477
207. Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230-240
208. Petit P, Lonjon R, Cociglio M, Sluzewska A, Blayac JP, Hue B et al. Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinical and pharmacokinetic correlates. Eur J Clin Pharmacol 1991; 41(6): 541-546
209. Preskorn S, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10: 88-95
210. Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring: Principles and practice. Ther Drug Monit 1993; 16: 611-641
211. Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: efficacy, safety, and cost effectiveness. J Clin Psychiat 1991; 52(Suppl.): 23-33
212. Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160-162
213. Preskorn SH, Fleck RJ, Schroeder DH. Therapeutic drug monitoring of bupropion. Am J Psychiatry 1990; 147: 1690-1691
214. Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. Acta Psychiatr Scand 1998; 98: 65-72
215. Rao ML. Modification of radioreceptor assay technique for the estimation of serum neuroleptic drug levels leads to improved precision and sensitivity. Psychopharmacol 1986; 90: 48-553
216. Rao ML, Staberock U, Baumann P, Hiemke C, Deister A, Cuendet C et al. Monitoring tricyclic antidepressant concentrations in serum by fluorescence polarization immunoassay compared with gas chromatography an HPLC Clin Chem 1994; 40: 29-933
217. Rasmussen BB, Brøsen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors. Ther Drug Monit 2000; 22: 43-154
218. Regenthal R, Krueger M, Koeppel C, Preiss R. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 1999; 15(7-8): 529-544
219. Reis M, Lundmark J, Bjork H, Bengtsson F. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002; 24(4): 545-553
220. Reisby N, Gram LF, Bech P, Nagy A, Petersen GO, Ortmann J et al. Imipramine: clinical effects and pharmacokinetic variability. Psychopharmacology 1977; 54(3): 263-272
221. RiveraCalimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 1973; 14(6): 978-986
222. Roberts CJ, Ford JM, Truman CA, Scott M, Makela PM, Wilcock GK. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease. Eur J Clin Pharmacol 1998; 54(9-10): 721-724
223. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics Journal 2002; 2(3): 191-196
224. Rochat B, Kosel M, Boss G, Testa B, Gillet M, Baumann P. Stereoselective biotransformation of the selective serotonin reuptake inhibitor, citalopram, and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 1998; 56: 15-23
225. Rodriguez dlT, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23(4): 435-440
226. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996; 7(6): 293-303
227. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52: 265-271
228. Rudorfer MV, Potter WZ. The role of metabolites of antidepressants in the treatment of depression [review]. CNS Drugs 1997; 7: 273-312
229. Sachse C, Brockmöller J, Bauer S, Roots I. Functional significance of a C →A polymorphism in introm I of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449
230. Sachse J, Härtter S, Müller MJ, Dragicevic A, Hiemke C. Therapeutisches Drug Monitoring von Quetiapin. Psychopharmakotherapie 2003; 10: 19-22
231. Sajbel TA, Carter GW, Wiley RB. Converting patients from brand-name clozapine to generic clozapine. Ann Pharmacother 2001; 35(3): 281-284
232. Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995; 29(3): 142-153
233. Schoerlin M-P, Mayersohn M, Korn A, Eggers H. Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects. Clin Pharmacol Ther 1987; 42: 395-404
234. Schou M. Forty years of lithium treatment. Arch Gen Psychiatry 1997; 54: 9-13
235. Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie 1997; 52: 895-911
236. Scordo MG, Spina E. Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 2002; 3(2): 201-218
237. Seeman P, Van Tol HHM. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharm-Mol Pharmacol Section 1995; 291: 59-66
238. Seiler W, Wetzel H, Hillert A, Schollnhammer G, Langer M, Barlage U et al. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology (Berl) 1994; 116(4): 457-463
239. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A et al. Analytical methods validation - bioavailability, bioeqivalence and pharmacokinetic studies. Pharm Res 1992; 9(4): 588-592
240. Simmons SA, Perry PJ, Rickert ED, Browne JL. Cost-benefit analysis of prospective pharmocokinetic dosing of nortriptyline in depressed. J Affect Disord 1985; 8: 47-53
241. Sindrup SH, Brøsen K, Gram LF, Hallas J, Skjelbo E, Allen A et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-287
242. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, Seroquel Study Group. Quetiapine in patients with Schizophrenia - A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54: 549-557
243. Spector R. Drug transport in the mammalian central nervous system: multiple complex systems. Pharmacology 2000; 60: 58-73
244. Spina E, Avenoso A, Facciolà G, Salemi M, Scordo MG, Ancione M et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology 2001; 153: 238-243
245. Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315(1-2): 137-155
246. Stein S, Schmoldt A, Schulz M. Fatal intoxication with melperone. Forensic Sci Int 2000; 113(1-3): 409-413
247. Strakowski SM, Keck PE, Jr., Wong YW, Thy rum PT, Yeh C. The effect of multiple doses of cimetidine on the steady-state pharmacokinetics of quetiapine in men with selected psychotic disorders. J Clin Psychopharmacol 2002; 22(2): 201-205
248. Tasker TCG, Kaye CM, Zussman BD, Link CGG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand 1989; 80(suppl. 350): 152-155
249. The Scottish Schizophrenia Research Group. The Scottish first episode Schizophrenia study. II. Treatment: imozide versus flupenthixol. Br J Psychiatry 1987; 150: 334-338
250. Thürmann PA, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs, Int J Clin Pharmacol Ther 1998; 36: 586-590
251. Tibballs J. Acute toxic reaction to carbamazepine: clinical effects and serum concentrations. J Pediatr 1992; 121(2): 295-299
252. Timmer CJ, Lohmann AAM, Mink CPA. Pharmacokinetic dose-proportionality study at steady state of mirtazapine from remeron tablets. Hum Psychopharmacol 1995; 10: S97-106
253. Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461-474
254. Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 Suppl 1: 13-18
255. Tokunaga H, Kudo K, Imamura T, Jitsufuchi N, Ohtsuka Y, Ikeda N. Plasma concentrations of antipsychotic drugs in psychiatric inpatients. Nippon Hoigaku Zasshi 1997; 51: 417-422
256. Torrens M, Castillo C, San L, del Moral E, Gonzalez ML, de laTorre R. Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program. Drug Alcohol Depend 1998; 52(3): 193-200
257. Troy SM, Parker VD, Fruncillo RJ, Chiang ST. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995; 35: 404-409
258. Tse G, Thompson D, Procyshyn RM. Generic clozapine: a cost-saving alternative to brand name clozapine? PharmacoEconomics 2003; 21(1): 1-11
259. Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but notof fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387
260. Ulrich S, Danos P, Baumann B, Müller D, Lehmann D, et al. Serum concentration of chlormethiazole and therapeutic effect in acute alcohol withdrawal syndrome - an open clinical trial. Ther Drug Monit 2002; 24: 446-454
261. Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiat 1998; 31: 163-169
262. Ulrich S, Neuhof S, Braun V, Meyer FP. Reduced haloperidol does not interfere with the antipsychotic activity of haloperidol in the treatment of acute schizophrenia, Int Clin Psychopharmacol 1999; 14: 219-228
263. Ulrich S, Wurthmann C, Brosz M, Meyer FP. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34: 227-263
264. Van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13(3): 169-172
265. Van Putten T, Marder SR. Variable dose studies provide misleading therapeutic windows (Letter). J Clin Psychoparmacol 1986; 6: 55-56
266. van Putten T, Marder SR, Wirshing WC, Aravagiri M, Chabert N. Neuroleptic plasma levels. Schizophr Bull 1991; 17(2): 197-216
267. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153(2): 1579-1584
268. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology 2000; 150(1): 15-23
269. Veefkind AH, Haffmans PMJ, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-208
270. veenstra DL, Higashi MK. Assessing the cost-effectiveness of pharmacogenomics. AAPS Pharmsci 2000; 2(article 29)(3): 1-11
271. Velazquez C, Carlson A, Stokes KA, Leikin JB. Relative safety of mirtazapine overdose. Vet Hum Toxicol 2001; 43(6): 342-344
272. Veuthey JL, Souverain S, Rudaz S. Column-switching procedures for the analysis of drugs in biologic samples. Ther Drug Monit 2004; 26(2): 161-166
273. Vuille F, Amey M, Baumann P. Use of plasma level monitoring of antidepressants in clinical practive - Towards an analysis of clinical utility. Pharmacopsychiatry 1991; 24: 190-195
274. Weigmann H, Gerek S, Zeisig A, Muller M, Härtter S, Hiemke C. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 2001; 23: 410-413
275. Wetzel H, Anghelescu I, Szegedi A, Wiesner J, Weigmann H, Härtter S et al. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 1998; 18: 2-9
276. Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA et al. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): 15S-20
277. Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: preliminary results. J Clin Psychopharmacol 1991; 11(1): 48-51
278. Zullino DF, Delessert D, Eap CB, Preisig M, Baumann P. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine. Int Clin Psychopharmacol 2002; 17: 141-143